Antibody therapy for non-Hodgkin's lymphoma

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 175-181

  Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Apoptosis; Complement; Monoclonal antibody; Non Hodgkin's lymphoma; Radioimmunoconjugate therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; HUMAN; IMMUNOLOGY; NONHODGKIN LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 7944220329     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin (2001) 51(1):15-36.
2. Valentine MA, Meier KE, Rossie S, Clark EA: Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein C. J Biol Chem(1989) 264(19):11282-11287.
3. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J (1988) 7(3):711-717.
4. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83(2):435-445.
5. Anderson KC, Bates MP, Slaughenhoupt BL, Schlossman SF, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood (1984) 63(6):1424-1433.
6. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF: The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol (1985) 135(2):973-979.
7. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother (2000) 48(12):673-683.
8. Hofmeister JK, Cooney D, Coggeshall KM: Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis (2000) 26(2):133-143.
9. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95(12):3900-3908.
10. Harjunpaa A, Junnikkala S, Meri S: Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms. Scand J Immunol (2000) 51(6):634-641.
11. Wurflein D, Dechant M, Stockmeyer B, Tutt AL, Hu P, Repp R, Kalden JR, van de Winkel JG, Epstein AL, Valerius T, Glennie M et al: Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res (1998) 58(14):3051-3058.
12. Elsasser D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M: HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood (1996) 87(9):3803-3812.
13. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS: Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res (2003) 9(16 Pt 1):5866-5873.
14. 1 phase of the cell cycle. J Immunol (1985) 135(6):3795-3801.
15. 2+ conductance found constitutively in B lymphocytes. J Cell Biol (1993) 121(5):1121-1132.
16. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood (2002) 99(4):1314-1319.
17. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction. Blood (2002) 99(3):1038- 1043.
18. Alas S, Ng CP, Bonavida B: Rituximab modifies the cisplatin- mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res (2002) 8(3):836-845.
19. Deans JP, Li H, Polyak MJ: CD20-mediated apoptosis: Signalling through lipid rafts. Immunology (2002) 107(2):176-182.
20. Petrie RJ, Deans JP: Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol (2002) 169(6):2886-2891.
21. van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van de Winkel JG, Weiner GJ: CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res (2003) 63(17):5595-5600.
22. Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med (2000) 6(4):443-446.
23. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcΓRIIIa gene. Blood (2002) 99(3):754-758.
24. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, Glennie MJ: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood (2003) 101(3):1045-1052.
25. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 171(3):1581-1587.
26. Weng WK, Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood (2001) 98(5):1352- 1357.
27. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy patients with relapsed low-grade non-Hodgkins lymphoma. Blood (1997) 90(6):2188-2195.
28. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol (1997) 15(10):3266-3274.
29. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 16(8):2825-2833.
30. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood (2001) 97(1):101-106.
31. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol (2002) 20(20):4261-4267.
32. Hainsworth JD: First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol (2003) 30(1 Suppl 2):9-15.
33. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 10(6):655-661.
34. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol (1999) 17(1):268-276.
35. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 19(2):389-397.
36. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 346(4):235-242.
37. Habermann TM, Weller EA, Morrison VA, Cassileth PA, Cohn JB, Dakhil SR, Gascoyne RD, Woda B, Fisher RI, Peterson BA, Horning SJ: Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Ann Meet Am Soc Hematol (2003):Abs 8.
38. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92(4):1184-1190.
39. Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V et al: Clinical activity and safety of combination immunotherapy with IFN-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica (2001) 86(9):951-958.
40. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J et al: Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol (2002) 117(4):828-834.
41. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C: Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99(1):67-74.
42. Jahrsdorfer B, Weiner GJ: Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin Oncol (2003) 30(4):476-482.
43. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukocyte Biol (2001) 69(1):81-88.
44. Leung SO, Goldenberg DM, Dion AS, Pellegrini MC, Shevitz J, Shih LB, Hansen HJ: Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol (1995) 32(17-18):1413-1427.
45. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 21(16):3051-3059.
46. Leonard JP, Coleman M, Matthews JC, Fiore JM, Dosik A, Shore T, Kapushoc H, Macri M, Wegener WA, Cesano A, Goldenberg DM: Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: Preliminary response data. Proc Am Soc Clin Oncol (2002):Abs 1060.
47. Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP: Epratuzumab: Targeting B-cell malignancies through CD22. Clin Cancer Res (2003) 9(10 Pt 2):3991S-3994S.
48. Micallef INM, Kahl BS, Gayko U, Cesano A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, Maurer MJ, White WL, Horning SJ, Habermann TM: A pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Ann Meet Am Soc Hematol (2003):Abs 2376.
49. Bains SK, Mone A, Yun Tso J, Lucas D, Byrd JC, Weiner GJ, Green JM: Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia (2003) 17(7):1357-1365.
50. Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I, Hall WC, Turner JF, Levitt D, Weiner GJ: Phase I study of Hu1D10 monoclonal antibody in patients with B-cell lymphoma. Proc Am Soc Clin Oncol (2001):Abs 1135.
51. Link BK, Wang H, Byrd JC, Leonard JP, Davis TA, Flinn I, Hall WC, Turner JF, Bowles J, Shannon M, Levitt D et al: Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen™ (Hu1D10). Ann Meet Am Soc Hematol (2001):Abs 4703.
52. Link BK, Kahl B, Czuczman M, Powell BL, Bartlett N, Leonard JP, Ansell S, Porcu P, Byrd JC, Lazarus HM, Flinn I et al: A phase II study of Remitogen™ (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. Ann Meet Am Soc Hematol (2001):Abs 2540.
53. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J et al: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 16(10):3257-3263.
54. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS: A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma (2001) 41(1-2):77-87.
55. Younes A, Hariharan K, Allen RS, Leigh BR: Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma (2003) 3(4):257-259.
56. Ansell S, Byrd J, Horwitz S, Davis T, Borchmann P, Engert A, Strair R, Khan K, Keler T, Graziano R, Blanset D et al: Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkins disease (HD) and anaplastic large cell lymphoma (ALCL). Ann Meet Am Soc Hematol (2003):Abs 632.
57. Bartlett NL, Bernstein SH, Leonard JP, Rosenblatt JD, Younes A, Carabasi MH, Bociek RG, Forero A, Miller D, Siegall CB, Sing AP: Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies. Ann Meet Am Soc Hematol (2003):Abs 2390.
58. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol (1996) 14(7):1974-1981.
59. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol (1998) 16(10):3270-3278.
60. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 17(12):3793-3803.
61. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol (2003) 21(7):1263-1270.
62. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol (2002) 20(10):2453-2463.
63. 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood (2003) 102(5):1606-1612.
64. 131Iodine-mAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma (2000) 38(1-2):91-101.
65. Denardo GL, Lamborn KR, Goldstein DS, Kroger LA, Denardo SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkins lymphoma and chronic lymphocytic leukemia. Cancer (1997) 80(12 Suppl):2706-2711.
66. 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res (2003) 9(10 Pt 2):3995S-4002S.
67. 90Y ibritumomab tiuxetan (Zevalin®) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol (2002):Abs 1064.
68. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol (2002) 20(18):3885-3890.